title: Evidence for plasticity of the dopaminergic system in parkinsonism.
abstract: A series of compensatory mechanisms within the dopaminergic system have been shown to maintain clinical function in the presence of dopamine loss. Experimental evidence for increased presynaptic dopamine turnover owing to increased dopamine synthesis, release, and reduced reuptake exists. Direct evidence that these mechanisms maintain extracellular dopamine levels is provided by intracerebral microdialysis techniques. Postsynaptic denervation supersensitivity clearly occurs with D2 dopamine receptors, although this is less evident with D1 receptors. Similarly, mechanisms of plasticity have been shown to be relevant in human postmortem and Positron Emission Tomographic studies of patients with Parkinson's disease. However, although presynaptic increases in dopamine turnover are well documented, postsynaptic D1 and D2 receptor changes have been more difficult to establish, mainly because of methodological difficulties. D2, but not D1, receptor increases have been documented in drug naive Parkinsonian patients with PET techniques. In transplantation of adrenal gland to striatum in animal models and patients with Parkinsonism where clinical improvement occurs, plasticity of host response may be as important as plasticity of the graft. Although some elements of the compensatory mechanism of dopamine plasticity may be deleterious, such as dyskinesias owing to dopamine receptor supersensitivity, the overall effect of delay and minimization of the clinical expression of disease is advantageous. An even greater understanding of the mechanisms involved may assist in developing future therapeutic strategies.
authors.affiliation: Department of Neurology, Austin Hospital, Heidelberg, Victoria, Australia.
authors.forename: G A
authors.initials: GA
authors.lastname: Donnan
authors.forename: D G
authors.initials: DG
authors.lastname: Woodhouse
authors.forename: S J
authors.initials: SJ
authors.lastname: Kaczmarczyk
authors.forename: J E
authors.initials: JE
authors.lastname: Holder
authors.forename: G
authors.initials: G
authors.lastname: Paxinos
authors.forename: P J
authors.initials: PJ
authors.lastname: Chilco
authors.forename: A J
authors.initials: AJ
authors.lastname: Churchyard
authors.forename: R M
authors.initials: RM
authors.lastname: Kalnins
authors.forename: G C
authors.initials: GC
authors.lastname: Fabinyi
authors.forename: F A
authors.initials: FA
authors.lastname: Mendelsohn
mesh_terms: D000311:Adrenal Glands / Q000637:transplantation; D000328:Adult; D000368:Aged; D000818:Animals; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology*; D003714:Denervation; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D008875:Middle Aged; D009473:Neuronal Plasticity; D009498:Neurotoxins / Q000633:toxicity; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology* / Q000601:surgery; D010302:Parkinson Disease, Secondary / Q000378:metabolism / Q000503:physiopathology / Q000601:surgery; D051381:Rats; D011954:Receptors, Dopamine / Q000378:metabolism / Q000502:physiology*; D013569:Synapses / Q000502:physiology; D014055:Tomography, Emission-Computed; D016042:Transplantation, Heterotopic
chemical_list: D009498:Neurotoxins; D011954:Receptors, Dopamine; D004298:Dopamine